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Abstract
 
Herpesviruses encode a variety of proteins with the potential to disrupt chemokine signaling, and
hence immune organization. However, little is known of how these might function in vivo. The
B cell–tropic murine gammaherpesvirus-68 (MHV-68) is related to the Kaposi’s sarcoma–associ-
ated herpesvirus (KSHV), but whereas KSHV expresses small chemokine homologues, MHV-68
encodes a broad spectrum chemokine binding protein (M3). Here we have analyzed the effect
on viral pathogenesis of a targeted disruption of the M3 gene. After intranasal infection, an M3
deficiency had surprisingly little effect on lytic cycle replication in the respiratory tract or the ini-
tial spread of virus to lymphoid tissues. However, the amplification of latently infected B cells in
the spleen that normally drives MHV-68–induced infectious mononucleosis failed to occur.
Thus, there was a marked reduction in latent virus recoverable by in vitro reactivation, latency-
associated viral tRNA transcripts detectable by in situ hybridization, total viral DNA load, and
 
virus-driven B cell activation. In vivo CD8
 

 
 T cell depletion largely reversed this deficiency,
suggesting that the chemokine neutralization afforded by M3 may function to block effective
CD8
 

 
 T cell recruitment into lymphoid tissue during the expansion of latently infected B cell
numbers. In the absence of M3, MHV-68 was unable to establish a normal latent load.
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Introduction
 
The traffic of leukocytes through lymphoid organs where
they are primed, and from blood vessels into sites of viral in-
fection and inflammation where they can be effective, is cru-
cial to normal immune function. Chemokines are chemotac-
tic cytokines that play a central role in these processes,
through their interactions with the G protein–coupled re-
ceptors expressed by all lymphoid cells (1, 2). Chemokines
also control the appropriate migration of antigen-presenting
cells. Consistent with an important role for chemokines and
chemokine receptors in antiviral defense, large DNA viruses
have developed a variety of strategies to disrupt chemokine
signaling (3, 4). Those described include the expression of
secreted chemokine binding proteins that block the interac-
tions of chemokines with cellular receptors or glycosami-
noglycans (5–9), chemokine-like proteins that can either
block or activate specific signaling pathways (10), and
chemokine receptor homologues that may adsorb chemo-
kines locally or may subvert normal signaling in infected cells
 
(11). But despite a large body of in vitro
 
 
 
data, the in vivo ef-
fects of viral chemokine blockade on host immunity are
largely unknown. So far, only the disruption of a secreted
35-kD chemokine binding poxvirus protein, vCKBPII, has
been analyzed in this regard (5, 8, 12): vCKBPII-deficient
mutants cause increased inflammation at the primary site of
infection, but show no evidence of attenuation relative to
 
wild-type (WT)
 
*
 
 virus (13, 14).
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Chemokine Neutralization and Gammaherpesvirus Latency
 
Gammaherpesviruses characteristically establish latency
in lymphocytes and thus have a particularly intimate associ-
ation with the host immune response. Murine gammaher-
pesvirus-68 (MHV-68) is a natural pathogen of murid ro-
dents (15) with a close genetic homology to Kaposi’s
sarcoma–associated herpesvirus (KSHV) and EBV (16–18).
MHV-68 infection of conventional mice has proved useful
in analyzing the roles of different viral genes (19–22) and
immune effector mechanisms (23–27) in gammaherpesvirus
pathogenesis. After intranasal infection, MHV-68 replicates
transiently in respiratory epithelial cells and spreads to lym-
phoid tissue where latency is established in B lymphocytes,
macrophages, and dendritic cells (28–31). The seeding of
virus to lymphoid tissue is followed by a massive amplifica-
tion of latently infected B cells in germinal centers (32, 33),
accompanied by antigen nonspecific B cell activation (34,
35) and an infectious mononucleosis illness analogous to
adolescent EBV infection (36). During this amplification,
lytic viral gene transcripts and infectious virus remain es-
sentially undetectable in lymphoid tissue, but abundant vi-
ral transfer RNA-like (vtRNA) transcripts can be identified
in splenic germinal centers by in situ hybridization (32, 33).
When latent virus first reaches the spleen, transcripts corre-
sponding to the MHV-68 M3 gene are detectable in
parafollicular areas (33), and reverse transcription (RT)-
PCR analyses have supported the idea that the M3 ge-
nomic region is transcribed during latency (37). The M3
gene encodes a 44-kD secreted protein, which is translated
from an abundant 1.4-kb early-late lytic transcript (38).
More recently the M3 gene has been shown to encode a
broad spectrum chemokine binding protein that neutralizes
cellular responses to chemokines in vitro
 
 
 
(7, 9). Crucially,
an M3-deficient mutant virus was found to lack detectable
secreted chemokine-binding activity (7). Here we have an-
alyzed the in vivo
 
 
 
pathogenesis of a virus deficient in M3 in
order to determine the role of chemokine blockade in
gammaherpesvirus pathogenesis and latency.
 
Materials and Methods
 
Viruses and Cell Culture.
 
Virus working stocks were prepared
by infection of baby hamster kidney (BHK-21) cells grown in
Glasgow’s modified Eagle’s medium containing 10% newborn
calf serum, 10% tryptose phosphate broth, 2 mM 
 
l
 
-glutamine,
100 U/ml penicillin, and 100 
 

 
g/ml streptomycin (complete-
GMEM). Cells were infected at low multiplicity (0.001 PFU/
cell) and harvested 3–4 d after infection as described previously
(21). Infectious virus titers were determined by suspension assay
using BHK-21 cells in complete-GMEM (21). After incubation
at 37
 

 
C in 5% CO
 
2
 
 for 4 d, monolayers were fixed in 10% formal
saline, counterstained with toluidine blue, and plaque numbers
enumerated using a plate microscope.
 
Recombinant Viruses.
 
Recombinant viruses containing a dis-
ruption of the M3 gene were generated as described previously
(7). In brief, M3LacZ and an independently derived mutant, des-
ignated M3LacZi, were generated by cotransfection of virion
DNA with linearized pM3MV10. This plasmid contains a 2,602-
bp fragment of MHV-68 (genomic coordinates 5,347–7,929)
with a cassette containing LacZ under control of the human cy-
 
tomegalovirus immediate early promoter inserted at a HincII site
(genomic coordinate 7,157), disrupting the M3 open reading
frame (ORF). The mutants, M3LacZ (7) and M3LacZi (this re-
port), were generated from independent transfections. To gener-
ate an M3 revertant, M3LacZ virion DNA was cotransfected
with pM3 which contains an intact M3 gene and flanking se-
quences (nucleotide coordinates 5,347–7,929). Recombinant vi-
ruses were identified by X-Gal staining, plaque purified three
times, and their genetic structures confirmed by Southern blot
hybridization.
 
In Vivo Infections.
 
Female BALB/c mice (Charles River Lab-
oratories) were inoculated intranasally at 5–6 wk of age with 4 
 

 
10
 
3
 
–10
 
4 
 
PFU of virus in 20 
 

 
l phosphate-buffered saline while
under halothane anesthesia. At various times after infection mice
were killed by intraperitoneal injection of sodium pentobarbitone
and lungs, spleen, and mediastinal lymph nodes (MLNs) re-
moved. For infectious virus assays, tissue homogenates were fro-
zen and thawed twice before suspension assay with BHK-21 cells.
Infectious center assays (21) were performed on dissociated
spleens and lymph nodes. For this assay, homogenized spleens
and MLNs were passed through a 140-
 

 
m filter to remove stro-
mal debris. Single cell suspensions were plated with BHK-21
cells, incubated for 5 d, fixed with 10% formal saline, and coun-
terstained with toluidine blue. Plaques were counted with a plate
microscope. All animal studies were conducted under approval of
UK Home Office Project Licence no. 80/1378.
 
CD8
 

 
 T Cell Depletion.
 
Mice were injected intravenously 2 d
before infection with 0.1 ml of ascitic fluid containing mAbs to
CD8
 

 
 (2.43; a gift from Dr. P.C. Doherty, St. Jude’s Children’s
Research Hospital, Memphis, TN) and every second day from
the day of virus infection by intraperitoneal injection of 0.1 ml
anti-CD8
 

 
 ascites. Depletion was 
 

 
99% effective, as determined
by flow cytometry of spleen cells.
 
Flow Cytometry.
 
Single cell suspensions were washed in PBS/
0.01% azide/0.1% BSA, blocked with 10% normal mouse serum,
and stained with CD69 FITC, anti-CD4 tricolor, or anti-CD8
tricolor (Caltag), and one of CD62L-PE, CD19 PE, or DX5-PE
(Becton Dickinson). After a 30-min incubation on ice, the cells
were washed and analyzed on a FACSort™ with LYSYS™ II
software (Becton Dickinson). Data were analyzed with FCSPress
1.0J software (www.fcspress.com).
 
RT-PCR Analyses of Virus Transcription.
 
mRNA was pre-
pared from virus infected BHK cells using a Direct mRNA kit
(Sigma-Aldrich). All RNA samples were DNAse-treated over-
night and phenol/chloroform extracted. Samples of RNA were
reverse transcribed for 1 h at 42
 

 
C. PCR was carried out with
Taq polymerase (Roche) according to the manufacturer’s instruc-
tions. The M2 forward primer corresponds to 5
 

 
-GGCTG-
GATATAGACTGGTTCA-3
 

 
 (nucleotides 4,212 to 4,232) and
reverse primer to 5
 

 
-TGTTACAGACTCTCACGCACA-3
 

 
(nucleotides 5,819 to 5,840). These M2-specific primers span the
M2 intron generating a predicted product size of 499 bp from
mRNA and 1,784 bp from viral DNA. The M4 forward primer
corresponds to 5
 

 
-GCCATAACATACTGGGCAGAAATAC-3
 

 
(nucleotides 9,054 to 9,079) and reverse primer to 5
 

 
-CAT-
GAATGACAATCTCTGGTACTGG-3
 

 
 (nucleotides 9,477 to
9,501) generating a predicted product size of 447 bp. PCR reac-
tions were carried out as follows: 1 cycle at 95
 

 
C for 5 min, 30
cycles at 95
 

 
C for 1 min, 65
 

 
C (54
 

 
C for M2) for 1 min, 72
 

 
C for
1 min followed by a final extension at 72
 

 
C for 10 min. PCR
products were analyzed on 1% agarose gels.
 
In Situ Hybridization.
 
Digoxigenin (Boehringer)-labeled ri-
boprobes corresponding to MHV-68 vtRNAs 1–4 were gener-
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ated by T7 transcription of pEH1.4 (32). In situ hybridization
was performed as described previously (39). In brief, 5-
 

 
m paraf-
fin-embedded sections were dewaxed in xylene, rehydrated
through graded ethanol solutions, treated with 100 
 

 
g/ml pro-
teinase K for 10 min at 37
 

 
C, and acetylated with 0.25% vol/vol
acetic anhydride-0.1 M triethanolamine. Sections were hybrid-
ized with labeled riboprobes in 50% formamide, 1
 

 
 SSC over-
night at 55
 

 
C. The stringent wash (0.1
 

 
 SSC, 30% formamide,
10 mM Tris, pH 7.5) was carried out at 58
 

 
C. Hybridized probe
was detected with alkaline phosphatase-conjugated anti-digoxi-
genin Fab fragments (Boehringer) according to the manufac-
turer’s instructions.
 
Southern Blot Hybridization Analysis.
 
Spleens were homoge-
nized in complete-GMEM and passed through 140-
 

 
m filters to
remove stromal tissue debris. Aliquots of 10
 
7 
 
cells were pelleted,
frozen, and later resuspended in 0.5 ml of TE (10 mM Tris, 50
mM EDTA, pH 8), lysed by the addition of SDS to a final con-
centration of 0.5%, and incubated with proteinase K (50 
 

 
g/ml)
at 37
 

 
C overnight. DNA was purified by phenol/chloroform ex-
traction and ethanol precipitation. 1 and 10 copy/cell reconstruc-
tions were prepared by the addition of known amounts of a
cloned PstI 1.2-kb repeat fragment (40) to 5 
 

 
g of purified BHK-
21 cell DNA. For Southern blot analyses, 5 
 

 
g of DNA was di-
gested with PstI and electrophoresed through a 0.8% Tris acetate
agarose gel. DNA was then transferred to a nitrocellulose mem-
brane and probed with an [
 

 
-
 
32
 
P]dCTP random prime-labeled
1.2-kb Pst repeat fragment. Hybridizations were performed at
65
 

 
C in 4
 

 
 SSC, 3
 

 
 Denhardt’s solution, 0.5% SDS, 0.2 mg/ml
sonicated salmon sperm DNA, 0.001 M phosphate buffer, and
10% dextran sulfate. Membranes were washed at 65
 

 
C three
times with 2
 
 
 
SSC, 0.1% SDS followed by two stringent washes
in 0.2
 

 
 SSC, 0.1% SDS at 65
 

 
C for 15 min. Filters were then
exposed to X-ray film for 7 d before development.
 
Results
 
Acute Phase Replication Kinetics of M3-deficient Mutants.
 
The construction of an M3-deficient virus, M3LacZ, that
lacks secreted chemokine binding activity has been de-
scribed (7). To determine the role of M3 in pathogenesis
we generated an independent mutant, M3LacZi, and a re-
vertant of M3LacZ, designated M3R. All viruses were free
of unrelated genomic rearrangements as determined by re-
striction enzyme analyses and Southern blot hybridization
(data not shown). RT-PCR analyses of infected cell RNA
demonstrated that insertion of the HCMV IE LacZ cassette
into the M3 gene had no detectable affect on the transcrip-
tion of the flanking M2 and M4 genes (Fig. 1). Single and
multistep growth curves revealed no obvious requirement
for M3 in lytic replication in vitro
 
 
 
(Fig. 2, a and b). Simi-
larly, no significant deficit in lytic phase replication was ob-
served in vivo after intranasal infection of mice with either
M3LacZ and M3LacZi, in comparison to WT MHV-68
from 3 to 7 d after infection (Fig. 3). However, lower lev-
els of virus from the lungs of animals infected with the M3-
deficient mutants was evident at 9 d after infection, sug-
gesting that an M3 deficit results in enhanced clearance of
lytic virus at late times after infection. Nonetheless, consis-
tent with the relatively normal kinetics of lytic phase respi-
ratory infection observed, flow cytometric analyses of cells
 
recovered from lungs by bronchioalveolar lavage showed
no evidence that an M3 deficit led to an enhanced infiltra-
tion of NK cells (DX5
 

 
) 3 d after infection or of activated
(CD62L
 
lo
 
) CD4
 

 
 or CD8
 

 
 T cells 9 and 13 d after infec-
Figure 1. RT-PCR analyses of M2 and M4 transcription during lytic
infection. RT-PCR analysis of M4 (a) and M2 (b) transcription in M3
LacZ, M3 LacZi, or WT-infected BHK cells. These data demonstrate
that insertion of the CMV LacZ cassette into the M3 gene has no detect-
able affect on the transcription of the neighboring M2 and M4 gene.
Figure 2. M3-deficient viruses exhibit normal growth kinetics in vitro.
(a) Multistep (0.01 PFU/cell) and (b) single-step (5 PFU/cell) growth
curves of M3-deficient and WT MHV-68 were performed to determine
any growth deficits in vitro. Infected BHK cell monolayers were harvested
at the times indicated and virus titers were determined by suspension assay.
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tion (data not shown). Thus, we conclude that M3 plays no
essential role in protecting MHV-68 against the immune
response during acute, lytic phase replication in the lung.
 
M3-deficient Mutants Are Defective for the Establishment of
Latency.
 
After epithelial infection, MHV-68 establishes a
latent infection in lymphoid tissue, colonizing germinal
centers (32, 33) and driving antigen-nonspecific B cell acti-
vation (34, 35). This is associated with an amplification of
latent virus and marks the onset of an infectious mononu-
cleosis-like illness that lasts several weeks before slowly re-
solving. Previous studies have shown that inhibiting MHV-
68 replication in the lung, through vaccination against a
lytic phase CD8
 

 
 T cell epitope, reduces the initial seeding
of virus to the draining MLNs but not the subsequent
course of latent virus amplification in either the MLNs or
spleen (41). Thus, lytic and latent virus amplification appear
to be distinct processes. The M3-deficient MHV-68 mu-
tants replicated relatively normally in the lung and infec-
tious center assays showed little difference between WT
and M3-deficient viruses in the extent of MLN coloniza-
tion 7 d postinfection (pi; Table I, top). However, the sub-
sequent amplification of M3-deficient latent virus was
grossly impaired (Table I, top). Restoring a functional M3
gene to M3LacZ (M3R) reversed the deficit and led to
normal amplification of latent virus in lymphoid tissues
(Table I, bottom).
On the basis that the level of recovery of virus by explant
culture is indicative of the level of virus latency, M3 ex-
pression appeared unnecessary for the initial seeding of vi-
rus to (mediastinal) lymphoid tissue, but essential for its
subsequent amplification in the spleen. Monitoring virus-
driven B cell activation gave a broadly equivalent picture.
At 7 d after infection, B cells (CD19
 

 
) recovered from the
MLNs were 62.8% activated (CD69
 

 
) with WT MHV-68,
45.0% with M3LacZ, 38.4% with M3LacZi, and 54.4%
with M3R (samples were pooled from five mice in each
case). Thus, while slightly greater activation was observed
 
with the M3
 

 
 viruses, in all cases the level far exceeded that
of naive control mice (
 
	
 
3% CD69
 

 
), consistent with a
fairly normal seeding of M3-deficient virus to the MLNs.
In contrast, the levels of splenic B cell activation 13 d pi
Figure 3. The M3 gene is not required for the initial phase of acute lung
infection. After intranasal inoculation with 104 PFU of WT MHV-68,
M3LacZ, or M3LacZi, four animals were sampled per virus 3, 5, 7, and 9 d
after infection. Titers were determined by suspension assay. Each point
represents the titer of an individual mouse.
 
Table I.
 
MHV-68 M3LacZ M3LacZi
Day pi 7 13 21 7 13 21 7 13 21
Spleen 1
 
	
 
1
 
a
 
1,860
 
	
 
1 2
 
	
 
1
 
	
 
1
 
	
 
1
 
	
 
1
 
	
 
1
2 3 390 17
 
	
 
1
 
	
 
1
 
	
 
1
 
	
 
1
 
	
 
1
 
	
 
1
3 13 830 4
 
	
 
1
 
	
 
1
 
	
 
1
 
	
 
1
 
	
 
1
 
	
 
1
4 7 140
 
	
 
1 	1 	1 	1 1 	1 	1
5 5 2,470 17 	1 	1 	1 3 	1 	1
6 13 880 12 	1 	1 	1 2 	1 	1
MLN 57 2,340 	10 17 	10 	10 64 	10 	10
MHV-68 M3LacZ M3LacZi M3R
Day pi 9 13 9 13 9 13 9 13
Spleen 1 15 50 3 	1 	1 	1 6 20
2 24 530 	1 	1 	1 	1 34 20
3 3 220 	1 	1 	1 	1 4 	1
4 10 60 	1 	1 	1 	1 	1 100
5 5 960 	1 	1 	1 	1 15 220
6 10 600 	1 	1 	1 	1 	1 270
MLN 510 1,390 	10 	10 	10 	10 860 810
Mice were infected intranasally with 4  103 PFU of M3LacZ, M3LacZi,
or WT MHV-68 (top), or M3LacZ, M3LacZi, WT MHV-68, or M3R
(bottom). Spleens were harvested at 7, 13, and 21 d pi (top), 9 and 13 d
pi (bottom). MLN samples were pooled from six mice per group prior to
assay. The latent virus load was determined in each instance by infectious
center assay. Preformed infectious virus was not detected at any time
point. At day 13, t test showed no significant difference in virus titer
between WT MHV-68 and M3R-infected mice (P  0.08).
aInfectious centers per 107 cells.
Figure 4. An M3 deficit leads to diminished virus-driven B cell activa-
tion. Spleens cells from animals (n 
 6) infected with the indicated viruses
were sampled at 13 d pi and analyzed by flow cytometry to determine the
proportion of activated (CD69) cells in the total CD19 B cell popula-
tion. Mean  SD values from each group of animals are shown.
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were considerably less with M3-deficient viruses than with
M3 controls (Fig. 4).
Quantification of Splenic Viral Load by In Situ Hybridization
Detection of Viral tRNAs. We next sought to analyze
splenic viral colonization by in situ hybridization after in-
tranasal infection of mice with either M3-deficient or WT
MHV-68. During MHV-68–induced infectious mononu-
cleosis, the virus expresses high levels of small tRNA-like
transcripts in latently infected lymphoid tissue, analogous to
the EBV-encoded small RNAs (EBERs) of EBV and UR-
NAs of Herpesvirus saimiri (21, 32). Although these vtRNAs
are also detectable in sites of lytic infection, they provide a
useful means to monitor viral latency in lymphoid germinal
centers, where in contrast to epithelial sites no other viral
transcripts are detectable (33). To follow the establishment
and maintenance of viral latency within the spleen, mice
were infected with either WT MHV-68 or M3LacZ, and
spleens removed from three animals per group at days 5, 7,
13, and 21 pi were processed for in situ hybridization using
a riboprobe specific for vtRNAs 1–4. M3-deficient virus
showed evidence of initial lymphoid colonization (day 7),
but entry into germinal centers was diminished and the
amplification of vtRNA-positive cells seen with WT
MHV-68 at day 13 pi failed to occur (Fig. 5). Table II
shows the total number and percentage of vtRNA-positive
of splenic follicles over time. At 7 d pi little difference in
Figure 5. In situ hybridization anal-
yses indicates clearance of M3-defi-
cient virus from the spleen. Spleens
from mice infected with WT MHV-
68 or M3LacZ were sectioned and
probed for vtRNA expression. Shown
is a representative panel of spleen sec-
tions analyzed for vtRNA expression
from each group of animals sampled at
5, 7, 13, and 21 d pi. Arrows indicate
vtRNA-positive cells.
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the number of vtRNA-positive splenic follicles was appar-
ent between WT MHV-68 and M3LacZ-infected mice. At
later time points (13 and 21 d pi) there was a pronounced
decrease in the number of splenic follicles positive for
vtRNA expression in animals infected with M3LacZ
(equivalent data, not shown, were obtained with M3LacZi)
in comparison to WT virus. Similarly, the number of
vtRNA-positive cells within individual splenic follicles was
little different between WT MHV-68 and M3LacZ-infected
mice at 7 d pi, but by 13 d pi, when a massive expansion of
vtRNA-positive cells in germinal centers was observed in
mice infected with WT MHV-68, the number of vtRNA-
positive cells was markedly reduced with the M3LacZ mu-
tant (Table III). This emphasizes that it was the expansion
of the latently infected population in germinal centers that
was most obviously lacking in the absence of M3. Finally,
Southern blot hybridization of viral DNA from spleens
sampled at 13 d pi showed a much lower level of M3-defi-
cient virus than WT MHV-68 (Fig. 6, a and b).
Clearance of M3-deficient Virus from the Spleen Is Immune
Mediated. The decline in latent load after fairly normal
initial seeding suggested that immune clearance of M3-
deficient virus from lymphoid tissue was occurring. Thus,
we wished to determine whether CD8 T cell depletion
could rescue the M3-deficient virus phenotype. Mice were
depleted of CD8 T cells from 2 to 12 d pi and latent vi-
rus in lymphoid tissue was quantitated by infectious center
assay (Fig. 7 a). CD8-depleted mice (n 
 8) infected with
WT-MHV-68 showed a mean 35-fold increase in recover-
Table II.
MHV-68 M3LacZ
Day
pi Mouse
Total 
number
of follicles
Number of
vtRNA-positive
follicles
Mean %
of total
vtRNA positive
Total
number
of follicles
Number of
vtRNA-positive
follicles
Mean %
of total
vtRNA positive
5 1 75 19 67 0
2 36 11 21 83 2 2
3 73 6 69 3
7 1 79 14 80 11
2 50 16 26 66 7 15
3 79 22 62 13
13 1 83 63 83 18
2 78 56 70 92 5 13
3 56 35 102 13
21 1 87 83 52 0
2 111 84 76 58 5 3
3 91 51 50 0
Quantitation of viral load by in situ hybridization detection of vtRNAs at 5, 7, 13, and 21 d pi. Similar results to M3LacZ were obtained with
M3LacZi (data not shown).
Table III.
Mean vtRNA cells/follicle
Day pi Mouse MHV-68 M3LacZ
5 1 11 1.6
2 6 1.4
3 1.5 0
7 1 4.6 3.7
2 3.5 2.2
3 3.5 1.9
13 1 47 5
2 17 4.8
3 12 3.5
21 1 27 1.4
2 24 0
3 29 0
Quantitation of viral load by in situ hybridization detection of vtRNAs
at 5, 7, 13, and 21 d pi. The mean number of vtRNA-positive cells
within individual follicles from mice infected with the indicated virus
are shown. Equivalent results to M3LacZ were obtained with M3LacZi
(data not shown).
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able splenic virus relative to the undepleted infected con-
trols. In contrast, animals (n 
 6) infected with either
M3LacZ or M3LacZi showed a mean 2,243- and 2,021-
fold increase in virus reactivation, respectively. In neither
case could the increase in recoverable virus consequent on
CD8 T cell depletion be accounted for by an increase in
the amount of preformed infectious virus (Fig. 7 b). Thus,
the mean number of infectious centers in WT MHV-68
infected CD8-depleted animals was 19,900/107 spleno-
cytes, whereas the mean level of infectious virus detected
was 105 PFU/107 disrupted splenocytes, that is 0.5% of the
plaque numbers generated in the infectious center assay.
With the M3-deficient mutants, M3LacZ and M3LacZi,
infectious virus accounted for 0.3 and 3% of plaques gen-
erated in the infectious center assay, respectively. We next
determined the affect of CD8 depletion on acute phase vi-
rus replication in order to ascertain whether there is any
obvious correlation between the extent of virus load in the
lung and levels of latent virus in the spleen at 9 and 13 d af-
ter infection. WT and revertant infectious virus titers in the
lungs of both depleted and undepleted mice were relatively
high at 9 d after infection (Fig. 7 c), whereas only low lev-
els of latent virus were detected in the spleens of these ani-
mals (Fig. 7 d). By day 13, the amount of infectious virus
Figure 6. Southern blot analyses of viral DNA load in the spleen. Mice
were infected with 4  103 PFU of WT MHV-68 or M3LacZ and
spleens were removed at 13 d pi. Total spleen DNA was extracted and
subjected to Southern blot analyses to determine the viral DNA load. For
each splenic DNA sample, 5 g of high molecular weight DNA was di-
gested with PstI. Restriction-cleaved DNA was transferred to nitrocellu-
lose and probed with a radiolabeled 1.2 kb Pst repeat fragment. 1 and 10
copy/cell reconstructions in uninfected BHK cell DNA are indicated. a
and b show two independent experiments.
Figure 7. Partial restoration of the latency deficit of M3-deficient viruses by in
vivo CD8 T cell depletion. Mice were immune depleted (CD8) or not
(CD8) with anti-CD8 mAb starting 2 d before infection with either WT
MHV-68 (n 
 8), M3LacZ (M3; n 
 6), or M3LacZi (M3i; n 
 6). Spleens from
all mice were harvested at 12 d pi. Infectious center assays were performed with (a) freshly isolated, or (b) freeze-thawed and sonicated spleen cells to
distinguish total from preformed infectious virus. Mean  SEM titers are shown. ND, virus not detected. Note that the log10 scale indicates that infec-
tious virus never exceeded 5% of the total recoverable by infectious center assay, implying that even after CD8 T cell depletion, the vast majority of in-
fected cells harbored latent virus. The differences between CD8 WT and CD8 M3 and CD8 M3i samples were not statistically significant (P  0.05
by t test). Individual lung virus titers from mice either CD8-depleted () or not () infected with either WT MHV-68, M3LacZ, M3 LacZi, or M3R
are shown (c). Latent virus was determined by infectious center assay from the spleens of animals sampled at 9 and 13 d after infection (d). Data points
shown below the horizontal dashed line represent tissue samples containing no detectable virus.
 o
n
 O
ctober 13, 2015
jem.rupress.org
D
ow
nloaded from
 
Published August 6, 2001
308 Chemokine Neutralization and Gammaherpesvirus Latency
was largely unchanged in the lungs of CD8-depleted mice
and considerably reduced in the case of WT and M3R-
infected immunocompetent controls. However, in both
groups of animals the amount of latent virus had increased
considerably. Thus, it would appear that the amplification
of latent virus in the spleen was not influenced greatly by
the absolute level of infectious virus in the lung. This ob-
servation is consistent with previous studies showing rela-
tively normal amplification of latent virus in lymphoid tis-
sue despite an almost complete absence of lytic replication
in the lung (26). After CD8 depletion, the M3-deficient vi-
ruses showed a decrease in infectious virus titers in the lung
but an increased level of latent virus at day 13 relative to
the day 9 time point (Fig. 7, c and d). Thus, here too there
was evidence of amplification of latent virus, independent
to the course of infection in the lung. The lower titers of
the M3-deficient viruses in the lungs at day 9 and 13 were
consistent with the somewhat more rapid clearance ob-
served previously (Fig. 3).
CD8 T cell depletion before infection also restored to
WT levels the level of splenic B cell activation by M3LacZ
virus (Fig. 8). As the immune depletion resulted in a partial
restoration of the capacity of M3-deficient mutants to es-
tablish latency in the spleen and drive B cell activation, we
were interested to determine whether the pattern of
vtRNA expression within splenic germinal centers was also
restored. To this end, CD8 T cell–depleted animals were
infected with either WT MHV-68 or the M3LacZ mutant
and the number of vtRNA-positive splenic follicles evalu-
ated at 11 d pi. Consistent with the partial restoration of
latency evaluated by explant cocultivation assay (Fig. 7
a), the mean percentage of splenic follicles containing
vtRNA-positive cells was 63% in animals infected with
M3LacZ and 81% with WT MHV-68. This contrasts with
a maximum of 22% of splenic follicles being vtRNA-posi-
tive in undepleted mice 7 or 13 d pi with M3-deficient vi-
rus (Table II). The restoration of vtRNA-positive follicle
numbers by CD8 T cell depletion correlated with a rela-
tively normal histological distribution of vtRNA-positive
cells within individual follicles (Fig. 9). Enumeration of the
mean number of vtRNA positive cells/follicle at 11 d pi
demonstrated that WT-infected CD8-depleted animals
contained 35.3 positive cells/follicle (n 
 3) while animals
infected with the M3-deficient mutant (M3LacZ) con-
tained 15 positive cells/follicle. Thus, after CD8 depletion,
the partial restoration of latency establishment by M3-defi-
cient MHV-68 apparent by infectious center assay is mir-
rored by an expansion of vtRNA-positive cells within the
spleen and relatively normal levels of B cell activation.
Discussion
The 44-kD MHV-68 M3 gene product has been shown
to encode a potent, broad range chemokine binding pro-
tein capable of inhibiting chemokine signaling (7, 9). To
determine the role of M3 in viral pathogenesis we have uti-
lized two independently derived viral insertion mutants in
which the M3 ORF was disrupted with a LacZ expression
cassette. The key observations from these phenotypic stud-
ies are that M3-mediated chemokine blockade makes little
contribution to initial lytic phase viral replication in the
lung, but that it is crucial for the amplification of latent vi-
rus in lymphoid tissue.
The fact that acute phase viral replication does not corre-
late with the efficiency of latency establishment (41) high-
lights the importance of the latent amplification process in
gammaherpesvirus colonization of the host. Here, despite
relatively normal lytic replication of M3-deficient mutants
in the lung, the amplification of latently infected cells in the
lymphoid tissue was grossly defective. The extent of initial
seeding to the MLNs does depend on lytic replication in
the lung (41), and little difference was observed between
WT MHV-68 and the M3-deficient mutants in the extent
of MLN latency and B cell activation 7 d pi. This was in
complete contrast to the dramatic reduction in amplifica-
tion of latent M3-deficient virus in the spleen at 13 d pi.
There was broad agreement in this finding between four
different measures: infectious center assay, vtRNA in situ
hybridization, Southern blot quantitation of viral DNA,
and the level of B cell activation. Quantitative differences
between the different assays in the precise degree of deficit
observed due to M3 disruption emphasize that not all cell
types and not all forms of viral latency may have been
equally affected. Nevertheless, the total latent virus load
was considerably reduced by every measure. Probably all
forms of viral latency were quantitatively deficient to some
degree in the absence of M3.
Figure 8. Effect of CD8 depletion on B cell activation mediated by
M3-deficient mutants. Dissociated splenocytes from either CD8-depleted
or normal animals (n 
 6) infected with WT MHV-68, M3LacZ, or
M3LacZi were sampled at 13 d pi and analyzed by flow cytometry to
determine the proportion of activated (CD69) cells in the total CD19
B cell population. Columns represent the mean  SD of the individual
mice within each group. Comparison by t test showed that the differ-
ence between WT MHV-68 and M3LacZi groups after CD8 T cell
depletion, although considerably reduced, remained statistically signifi-
cant (P 	 0.002); the difference between WT MHV-68 and M3LacZ
groups after CD8 T cell depletion was not significant (P 
 0.12).
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M3-deficient virus was not essential to establish latency at
the level of the individual cell, as there was normal initial
seeding of latent virus to the MLNs, and CD8 T cell de-
pletion led to fairly normal latent viral loads. The deficit in
latency was instead at the level of the host, reflecting a re-
quirement for immune evasion to increase the number of la-
tently infected cells. Intriguingly, disruption of the homolo-
gous M1 gene of MHV-68 via insertion of a CMV LacZ
cassette has no obvious effect on latency establishment (19,
21). This suggests that these genes have diverged to fulfil
very different roles. We found normal transcription of the
M2 and M4 genes after infection with the M3 mutants, as
judged by RT-PCR analyses, indicating that insertional mu-
tagenesis of M3 had no detectable effect on transcription of
these neighboring genes. Thus, the observed phenotype of
the M3-deficient mutants is most likely due to a deficiency
in secreted chemokine binding activity and our conclusions
are based on the assumption that no other viral functions
have been compromised by insertion of the LacZ reporter
gene cassette at the M3 locus. We also consider it unlikely
that an immune response to -galactosidase is responsible for
the in vivo clearance of the M3LacZ insertion mutants, as
earlier work has shown that insertion of the same LacZ cas-
sette in place of the M1 gene, or insertion of this reporter
gene cassette into the tRNA 3 locus, has no detectable affect
on the latency competence of theses recombinants (21).
The partial reversal in the capacity of M3 mutant viruses
to establish latency in the spleen after in vivo CD8 T cell
depletion suggests that M3 chemokine blockade protects
WT MHV-68–infected splenocytes against elimination by
this subset. Although it has been reported that depletion
with anti-CD8 antibody may lead to detrimental CD4-T
cell responses (42), we consider such detrimental affects to
be unlikely in the context of MHV-68 infection. Previous
studies have shown that anti-CD8 treatment has no detect-
able affect on the frequency of CD8 dendritic cells, which
may play a role in driving CD4 responses (42), and CD4 T
cell immunity appears unaffected after CD8 depletion of
MHV-68 infected animals (43). It has also been established
that CD4/CD8 double depletion has considerably greater
effect than CD8 depletion alone, indicating that CD4 T
cell immunity and CD4-dependent virus-specific antibody
are not diminished by anti-CD8 treatment (23, 26). Fur-
thermore, the phenotypic reversion achieved by CD8 T
cell depletion, namely amplification of latent MHV-68 in
lymphoid tissue, is CD4 dependent and does not occur
Figure 9. A restoration of M3-deficient virus
phenotype in CD8 T cell–depleted animals.
CD8 T cell–depleted mice were infected with
WT MHV-68 or M3LacZ and spleens were re-
moved for in situ hybridization analysis of vtRNA
expression at 11 d pi. Three representative spleen
sections are shown for WT MHV-68 or M3LacZ-
infected mice. Comparison with the time course il-
lustrated in Fig. 5 illustrates the extent of pheno-
typic reversion of the M3 deficit achieved by im-
mune depletion. Equivalent results to M3LacZ
were obtained with M3LacZi (data not shown).
 o
n
 O
ctober 13, 2015
jem.rupress.org
D
ow
nloaded from
 
Published August 6, 2001
310 Chemokine Neutralization and Gammaherpesvirus Latency
when the CD4 T cell response is impaired (30, 44).
Nonetheless, as the effect was incomplete, other effectors
such as CD4 T cells and NK cells may also contribute and
such effectors may play a more important role in the en-
hanced clearance of M3-deficient virus from the lungs of
infected mice, as there was little evidence of CD8 T cell
depletion reversing the deficit in lytic replication. The im-
plication is that M3 expression inhibits a range of cellular
immune effectors to prevent the elimination of latent
MHV-68 from lymphoid tissue. The fact that the CD4 T
cell subset also drives latency expansion through the provi-
sion of B cell help underlines the potential complexity of
lymphocyte interactions within MHV-68–infected lym-
phoid tissue. In situ hybridization studies have demon-
strated that at least quantitatively, M3 transcription occurs
primarily in the paracortical areas of splenic follicles. This is
maximal early in lymphoid colonization, with M3 tran-
scription downregulated during the expansion of vtRNA
cells in germinal centers (33). Paradoxically, a lack of M3
expression had little affect on the number of tRNA cells in
paracortical areas, but a profound effect on vtRNA expres-
sion within germinal centers. It may be that M3 protein se-
creted in paracortical areas of lymphoid follicles allows cells
expressing an immunogenic latency program to enter ger-
minal centers where a relatively physiological amplification
of activated B cells can occur. A recent report found latent
MHV-68 in three spleen cell types — B cells, macrophages,
and dendritic cells — after intranasal infection (28). Cer-
tainly removing the protection afforded by M3 abrogated
the generation of vtRNA-positive germinal center cells.
But whether M3 is actually expressed by virus-infected B
cells in germinal centers remains to be seen. Analyzing viral
gene transcription within these different cell types could be
one way forward in understanding exactly how MHV-68
has adapted to life in a chemokine-rich world.
Given the abundant expression of M3 during lytic cycle
infection (33, 38, 45), it was surprising that an M3 deficit
had little effect on the initial stages of MHV-68 replication
in the lung. However, the consistent detection of enhanced
clearance of M3-deficient mutants at late times after infec-
tion suggests that chemokine neutralization afforded by M3
has a role in optimizing the late stages of acute phase replica-
tion. It may be that tissue damage, at least during the initial
stages of acute phase replication in the lung, results in such
an abundance of chemokines that M3-mediated blockade is
overwhelmed. Lytic replication is notably lacking in MHV-
68–infected lymphoid tissue, and the lack of tissue damage
and consequent innate immune activation in this site may be
crucial for successful immune evasion by M3. We have re-
cently described an MHV-68 protein, K3, that blocks anti-
gen presentation to CD8 T cells by downregulating MHC
class I–restricted antigen presentation (46). K3 may be insuf-
ficient to escape CD8 T cell recognition of virus-infected
B cells, which in contrast to fibroblasts have high levels of
constitutive antigen presentation. In addition, unlike M3,
K3 expression is probably restricted to lytic replication and
thus may not prevent the recognition of latency-related
CTL targets. It is possible that M3 has a greater role during
reactivation from latency. At least initially, this should not
generate as much tissue damage as primary infection.
Herpesviruses are generally considered to establish la-
tency as a default program, when immediate early gene ex-
pression critical for the initiation of lytic cycle replication is
lacking (47). To our knowledge our phenotypic character-
ization of an M3-deficient virus represents the first descrip-
tion of a viral gene essential for the normal establishment of
latency. One implication is that a strategy of immune eva-
sion is critical for the programmed entry of the viral ge-
nome into latency. A variety of herpesviruses cause an acute
mononucleosis syndrome, probably driven by viral amplifi-
cation; the KSHV chemokine antagonist, vMIP-II (48, 49),
suggests that this virus at least has evolved an independent
approach to the same goal as MHV-68. Chemokine block-
ade may indeed prove to be a common requirement for ef-
fective host colonization by lymphotropic herpesviruses.
That this might provide a potential target for effective anti-
viral therapy is reason enough to further investigate M3.
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